Notice ID: a279619059084f9e81002d03b7d36aeaAward NoticeAwardedArchived
R--Autonomous Underwater Vehicle (AUV) Operation and
Awarded on September 21, 2026. Full description on SAM.gov.
Awarded tounder 1305M424D0047 (source: SAM.gov award notice)• $82.8K
Overview
- Posted
- September 21, 2026
- Notice type
- Award Notice
- NAICS
- 541990: All Other Professional, Scientific, and Technical Services
- Agency
- Department of CommerceNATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION
Notice details
- Office
- DEPT OF COMMERCE NOAA
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
- Award date
- Sep 21, 2026
- Award amount (SAM.gov award notice)
- $82.8K
Identifiers
- Solicitation number
- 1305M326Q0505
- Notice ID
- a279619059084f9e81002d03b7d36aea
- Award number (PIID)
- 1305M424D0047
Description
Autonomous Underwater Vehicle (AUV) Operation and Maintenance Services for the National Marine Fisheries Service Northwest Fisheries Science Center (NWFSC)
Award Overview
Award Number
1305M424D0047
Award Amount (SAM.gov award notice)
$82.8K
Award Date
Sep 21, 2026
Awardee
Awardee UEI
L5C9GFPC8LY4
Awardee CAGE Code
8JMP3
Awardee Address
4625 Cherry Valley Dr, Rockville, MD 20853, UNITED STATES
Delivery Order Number
1305M326F0265
Original Solicitation
Notice ID: a279619059084f9e81002d03b7d36aea
Posted Date: Sep 21, 2026
Original Response Deadline: Not specified
Task Orders Under This IDV
Top 10 by total obligated
- $3.8MSigned Jul 21, 2026
- $3.8MSigned Aug 4, 2026
- $3.6MSigned Jun 23, 2026
- $2.2MSigned Sep 17, 2026
- $1.1MSigned Sep 25, 2025
- $1.1MSigned Mar 11, 2026
- $160.2KSigned Aug 17, 2026
- $109.8KSigned Sep 4, 2026
- $106.5KSigned Sep 21, 2026
- $82.8KSigned Sep 21, 2026
More From This Vendor
Top 5 most recent
- $82.8KSigned Oct 21, 2026
- $106.5KSigned Sep 21, 2026
- $82.8KSigned Sep 21, 2026
- $2.2MSigned Sep 17, 2026
- $79.3KSigned Sep 15, 2026
Contacts
Contracting Officer
Primary Contact
Documents
No documents available.
Lifecycle
- 3Version 3Award NoticeArchivedCurrent
R--Autonomous Underwater Vehicle (AUV) Operation and
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
53% | Awarded | Open | |
***NOAA'S ACQUISITION & GRANTS OFFICE, EASTERN ACQUISITION DIVISION-NORFOLK, NATIONAL GEODETIC SURVEY (NGS) OFFICE INTENDS TO NEGOTIATE, ON A SOLE SOURCE BASIS, UNDER AUTHORITY OF FAR 13.106-1(b)(1), WITH H.A.S. IMAGES, INC OUT OF DAYTON, OH TO PREPARE AND PACK ROLLS OF ARCHIVAL AERIAL FILM FOR SHIPMENT. ***THE SOLE SOURCE DETERMINATION IS BASED ON THE NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION'S (NOAA) REQUIREMENT THAT H.A.S. IMAGES IS THE SOLE PROVIDER TO PREPARE AND PACK ROLLS OF ARCHIVAL AERIAL FILM FOR SHIPMENT BECAUSE THE COMPANY IS THE SOLE CUSTODIAN OF NGS’s ENTIRE COLLECTION OF AERIAL PHOTOGRAPHY. THE ENTIRE HOLDINGS OF NGS AERIAL PHOTOGRAPHY FILM ROLLS ARE CURRENTLY LOCATED AT H.A.S. IMAGES, INC. H.A.S. IMAGES, INC. HAS A SECURE PRIVATELY-OWNED FACILITY WITH ENVIRONMENTALLY-CONTROLLED SPACE FOR STORING EXPOSED AERIAL FILM. AS ALL OF THE FILM THAT IS TO BE PACKED, INVENTORIED AND CATALOGED FOR FOLLOW-ON SHIPMENT TO NARA AND FRC IS CURRENTLY IN THIS PRIVATELY-OWNED BUSINESS, H.A.S. IMAGES, INC. IS UNIQUELY POSITIONED TO PROVIDE THIS SERVICE AND THEY DO NOT HAVE ANY AUTHORIZED PARTNERS WHO CAN PROVIDE THIS SERVICE. ***THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE PROPOSALS AND NO SOLICITATION PACKAGE IS AVAILABLE. HOWEVER, FIRMS THAT BELIEVE THEY CAN FULLY MEET THE GOVERNMENT'S REQUIREMENTS MAY SUBMIT SUBSTANTIATING DOCUMENTATION IN WRITING TO THE IDENTIFIED POINT OF CONTACT WITHIN 15 DAYS AFTER PUBLICATION OF THIS SYNOPSIS. SUCH DOCUMENTATION WILL BE EVALUATED SOLELY FOR THE PURPOSE OF DETERMINING WHETHER OR NOT TO CONDUCT THIS PROCUREMENT ON A COMPETITIVE BASIS. A DETERMINATION BY THE GOVERNMENT NOT TO CONDUCT A COMPETITIVE PROCUREMENT, BASED UPON RESPONSES TO THIS NOTICE, IS SOLELY WITHIN THE DISCRETION OF THE GOVERNMENT. ORAL COMMUNICATIONS ARE NOT ACCEPTABLE IN RESPONSE TO THIS NOTICE. | 48% | Special Notice | 08/30/2024 |
This is not a solicitation announcement. This is a Sources Sought Notice (SSN) only. This SSN is issued solely for market research and planning purposes – it does not constitute a Request for Proposal (RFP) or a promise to issue an RFP in the future. Further, the SSN does not commit the Government to contract for any supply or service whatsoever. The FDA is not seeking proposals and will not accept any unsolicited proposals. Responders are advised that the U.S. Government will not pay for any information or administrative costs incurred in response to this SSN; all costs associated with responding to this SSN will be solely at the expense of the interested respondents. Not responding to this SSN does not preclude participation in any future RFP, if issued. The purpose of this sources sought synopsis is to gain knowledge of potential qualified vendors to include potential 8(a) vendors 8(a) relative to the North American Industry Classification System (NAICS) code and capable of providing multidisciplinary scientific and regulatory professional services in support of FDA Centers and Offices. Responses to this Sources Sought Notice will be used by the Government to make appropriate determinations about potential sources. Project Title: FDA Scientific and Regulatory Support Services (SRS) IDIQ Background/Overview: The Food and Drug Administration (FDA) is a science-based regulatory agency critically important to the stability of the nation's public health and health care systems. FDA protects and promotes the health and safety of all Americans by enhancing the availability of safe medical products, foods, and animal products, and by promoting innovation that addresses unmet medical and public health needs. FDA decisions must be based on the best available scientific data and employ the best tools and methods available to ensure products meet the highest quality standards, while fostering innovation in the products it regulates. In support of its regulatory mission, FDA conducts scientific research across a broad range of disciplines including vaccines, drug safety, food safety, medical devices, biologics, toxicology, radiological products, and more. FDA's science is increasingly data-centric, complex, and collaborative, involving multidisciplinary groups across its Centers and Offices. Within the Center for Drug Evaluation and Research (CDER), the Office of Computational Science (OCS), established under the Office of Translational Sciences, supports the data management, technical, and analytic needs of the regulatory review process. OCS manages and supports analytical tools, data standards, and computing infrastructure that form the backbone of modern regulatory review for medical products. Purpose: The FDA is seeking information from experienced sources in Scientific and Regulatory Support Services as it is contemplating the establishment of a Indefinite Delivery Indefinite Quantity (IDIQ) to such services. The FDA’s primary objective for this effect is to obtain Contractor services related to scientific and regulatory support across a broad range of mission requirements. Depending on the requirement, services may support scientific research, regulatory review, clinical and non-clinical analyses, epidemiology and surveillance, scientific data interpretation, laboratory activities, technical writing, training, and scientific program coordination. Objectives: The objective of the contemplated SRS acquisition is to provide FDA with responsive, high-quality scientific and regulatory support across a broad range of mission requirements. Depending on the task order, services may support scientific research, regulatory review, clinical and nonclinical analyses, epidemiology and surveillance, scientific data interpretation, laboratory activities, technical writing, training, and scientific program coordination. The Government is interested in sources capable of providing the scientific depth and operational capacity needed to: Conduct scientifically sound analyses and prepare defensible, traceable technical products supporting FDA review and public-health decisions. Provide qualified personnel across multiple scientific and regulatory disciplines, including specialized and emerging areas. Support clinical and nonclinical study-data review, standardized scientific datasets, statistical computing, data fitness, quality assessment, and interpretation. Respond to multiple simultaneous task orders, changing priorities, time-sensitive scientific questions, and evolving requirements across FDA organizations. Maintain scientific quality, data integrity, documentation, confidentiality, and continuity of performance. Deliver effective scientific training, technical writing, knowledge transfer, and program-management support tied directly to scientific and regulatory missions. Project Requirements: The following descriptions are illustrative of the types of services that may be ordered. They are provided to inform industry responses and do not establish final task-order requirements. Each task order would define its own objectives, tasks, deliverables, performance expectations, staffing qualifications, and period of performance. Scientific Research and Regulatory Review Support: Support scientific investigations, literature and evidence reviews, research planning, study design, methodological assessments, scientific consultations, and technical analyses relevant to FDA-regulated products. Prepare scientific assessments, briefing materials, review support documentation, and other products that allow Government scientists and reviewers to evaluate scientific evidence and communicate findings. Provide subject-matter expertise to address complex or emerging regulatory science questions. Clinical and Nonclinical Study-Data Review and Analysis: Support the scientific review of clinical and nonclinical datasets submitted for regulatory purposes, including data fitness and completeness assessments, exploratory safety analyses, descriptive and inferential statistical analyses, and preparation of tables, listings, figures, and visualizations. Subject-matter expertise in applicable clinical and nonclinical study-data standards, including CDISC SDTM, ADaM, and SEND, is particularly relevant to these services. The RRS BPA describes review-oriented services that assess study data and produce analyses for FDA reviewers; SRS would focus on the scientific and analytical performance of those services rather than maintenance of the underlying software platforms. Epidemiology, Biostatistics, Pharmacovigilance, and Surveillance: Conduct epidemiological and Pharmacoepidemiological research, biostatistical analyses, pharmacovigilance assessments, signal detection and evaluation, public-health surveillance, and interpretation of real-world data and evidence as required by individual scientific programs. Activities may include protocol and analysis-plan support, assessment of study limitations and bias, statistical programming, results interpretation, and technical reporting. Scientific Data Standards, Quality, and Analytics: Provide scientific expertise related to data standards, controlled terminology, study-data interpretation, data quality and fitness, and reproducible analytical methods. Support scientific data preparation and validation, biostatistics, bioinformatics, computational science, and other specialized analyses when the primary deliverable is scientific or regulatory in nature. Distinguish these activities from enterprise database administration, application development, platform engineering, and IT operations. Laboratory and Specialized Scientific Support: Provide laboratory-related scientific and technical expertise, research assistance, analytical method support, study coordination, quality documentation, and interpretation or reporting of laboratory findings where required by a task order. Respondents should identify the specific laboratory disciplines, facilities, qualifications, and methods they can support rather than assume that all clinical trial operations or laboratory testing will be included. Scientific Writing, Training, Knowledge Management, and Communications: Develop scientific reports, regulatory review support materials, technical summaries, study documentation, research publications, presentations, training curricula, and knowledge-transfer materials. Provide specialized scientific and regulatory training, including instruction related to study-data standards and analytical methods. Communications and knowledge-management work should be directly connected to scientific or regulatory activities rather than general enterprise communications or IT support. Scientific Program and Project Management: Plan and coordinate scientific studies and projects; manage milestones, deliverables, schedules, staffing, and technical reporting; facilitate multidisciplinary collaboration; track performance and quality; and support continuity during transitions. Such activities must be integral to scientific and regulatory service delivery, not standalone enterprise IT project management. Scope Distinctions: The contemplated SRS acquisition is not intended to replace vehicles for enterprise IT architecture, systems or application development, cloud or data-platform operations, infrastructure administration, software maintenance, generalized service-desk support, or other predominantly IT functions. Where a task combines scientific analysis and enabling technology, the Government will determine the appropriate vehicle and scope based on the primary purpose of the requirement. The final boundary between SRS and remaining RRS or other vehicles is subject to FDA and OAGS confirmation. Capabilities and Technical Experience: Interested small businesses should submit a concise capability statement demonstrating relevant, actual performance and capacity to satisfy the contemplated requirements. Responses should clearly distinguish capabilities performed by the respondent from those provided by subcontractors, affiliates, or proposed teaming partners. FDA is particularly interested in the following: Relevant Experience: Describe comparable scientific and regulatory engagements, customer organizations, contract or order identifiers where releasable, approximate value, period of performance, work performed, disciplines supported, and measurable outcomes. Explain how the experience relates to the breadth and complexity of the contemplated SRS work. Scientific and Regulatory Disciplines: Describe the service areas the respondent can perform, with concrete examples involving scientific research, regulatory analysis, clinical and nonclinical datasets, statistical methods, epidemiology, laboratory work, scientific writing, and training as applicable. Do not claim disciplines for which experience cannot be substantiated. Workforce and Concurrent Delivery Capacity: Describe the organization's demonstrated ability to recruit, retain, and deploy highly specialized scientific and regulatory professionals across a broad range of disciplines, including individuals with advanced degrees, niche technical expertise, and experience supporting complex scientific and regulatory programs. FDA recognizes that certain highly specialized skill sets may require recruitment from an international talent pool, including individuals holding or requiring employment-based visa sponsorship (e.g., H-1B) or other appropriate work authorization. Respondents should describe their experience recruiting and retaining such personnel, managing applicable sponsorship and work authorization requirements, and mitigating potential staffing disruptions during contract transitions. Responses should also address the organization's ability to fill hard-to-recruit positions, maintain continuity of specialized expertise, accommodate surge requirements, and support multiple concurrent task orders. Where available, provide representative workforce metrics, such as available staffing capacity, average time-to-fill for specialized positions, and retention or attrition trends. Include a representative example demonstrating the organization's ability to respond to surge requirements or manage concurrent scientific and regulatory assignments, including its approach to staffing continuity, resource allocation, and timely delivery. Scientific Quality and Data Practices: Describe scientific quality-control procedures, independent review, data integrity and reproducibility practices, use of applicable scientific standards, confidentiality controls, and experience handling sensitive regulatory or research information. Representative Complex Requirement: Describe one or more specific scientific or regulatory assignments presenting substantial technical complexity, urgent timelines, multidisciplinary coordination, or simultaneous delivery requirements. Explain the challenge, approach, expertise, staffing considerations, deliverables, and outcomes. AI, Emerging Technology, and Responsible Use: Describe the organization's experience applying artificial intelligence (AI), machine learning (ML), or other emerging technologies to scientific research, regulatory review, or related analytical activities, as applicable. Provide representative examples of these applications and describe the organization's approaches to validating outputs, maintaining scientific integrity, ensuring appropriate human oversight, and managing associated risks. Identify any experience implementing responsible AI practices or governance frameworks, particularly in federal or regulated environments. Teaming and Prime-Contractor Role: Describe anticipated prime, subcontracting, joint-venture, or teaming arrangements and the work each participant would perform. Explain how the prime would exercise management and technical oversight while meeting applicable small-business requirements. Contract Structure Feedback: Identify whether the firm could support the full breadth of contemplated services or a defined subset and explain why. Instructions for Responses: Your responses to the questions provided below will assist the Government in selecting the appropriate acquisition method. Page limit: Maximum 15 pages (font size Times New Roman 11 or larger). A copy of the company capability statement will also be accepted (but not in place of the responses to the below questions). The anticipated period of performance is a 5-year ordering period. After review of the responses received, a pre-solicitation synopsis and formal solicitation may be published on SAM.gov. In addition to responses to the below questions, each vendor responding to this SSN shall also fill out and provide responses to “Attachment B-Vendor Feedback Form.” The Vendor Feedback Form is not included in the 15-page limit. A copy of the company capability statement will also be accepted (but not in place of the responses to the below questions or the Vendor Feedback Form). Responses to this notice must include company name, address, point of contact, size of business pursuant to the NAICS code, and must respond to the following questions: Is your business a small business under the NAICS code? Is your firm certified under Section 8(a) of the Small Business Act? Included is a draft Statement of Work that is inclusive of the anticipated Task Areas (Attachment A). All interested parties can provide written opinions on the draft Statement of Work. All opinions expressed should focus on strengthening the draft Statement of Work Tasks to ensure industry understands and comprehends the government’s requirements. Business Status Provide the legal business name and address Primary point of contact and the contact information SAM.gov Unique Entity Identifier (UEI) CAGE code Proposed NAICS code and size status Applicable small-business socioeconomic designations (including 8(a), HUBZone, service-disabled veteran-owned, veteran-owned, women-owned, or small disadvantaged business, as applicable) Identify whether the respondent proposes to participate as prime contractor, joint venture, or subcontractor Responses to this notice shall be submitted via e-mail to Amanda Edger, Contract Specialist, at Amanda.Edger@fda.hhs.gov (with a CC: to Ian Weiss, Contracting Officer, at Ian.Weiss@fda.hhs.gov), by November 23, 2026, at 2:00 pm EST. After a review of the received responses, a pre-solicitation synopsis and formal solicitation may be published on SAM.gov. No solicitation is currently available. This is not a request for proposals and in no way obligates the Government to award any contract. Responses to this Sources Sought Notice will not be considered adequate responses to the solicitation, a request to be added to a prospective offerors list, or a request to receive a copy of the solicitation. Ref. No. FDA-RFI-75F40127R00007/ALP No. OMITS-2027-136942. | 45% | Market Research | 11/23/2026 |
Special Notice: Thank you for your interest and feedback during our market research for the Warfighter Acquisition Solutions and Programs (WASP) - A&AS V Successor Requirement. The Air Force has made the decision to pursue issuing GSA OASIS+ task orders using the unrestricted pool for any future/follow-on requirements. Thank you and have a great day. | 45% | Special Notice | 11/05/2026 |
The Government requests that industry provide feedback/comments on the attached draft documents, specifically, the following: --General feedback on the Evaluation Criteria --Feedback on the overall acquisition strategy of awarding to any and all Offerors who are at our MTTR of 30,000 points -- Whether the offeror would submit a proposal against the Final RFP (estimated to be released week of 9 May) based on all information received to date --What the offeror estimates their initial self-score would be --Comments on the offeror's experience with onramping/offramping procedures and which procedures have been most successful from an industry perspective. Update 11 Apr 2022: A list of questions and answers from the one-on-one opportunity has been posted. No further one-on-one opportunities are available. Further questions or feedback may be submitted to the Contracting Officer at elijah.welenc@us.af.mil. Update 11 May 2022: Updated draft documents, a list of responses to industry questions, and critical information about use of the PIEE Solicitation Module for submission of proposals have been posted. Update 24 June 2022: The Government, in response to feedback provided by industry, is making significant changes to the draft documents, and will release new draft documents as soon as they are available. Potential offerors are encouraged to continue to monitor sam.gov. The awardees on the predecessor IDIQ, A&AS IV, were as follows: CAE USA Mission Solutions, Inc. Mission Essential Group, LLC Validatek, Inc. Itility, LLC The government requests that all potential offerors stop contacting the DOCPER office regarding A&AS V. Clarification regarding documentation of SOFA status is forthcoming in the next documentation release. Update 30 June 2022: The Government changed over PCO responsibilities from Mr. Elijah A. Welenc to Capt Teresa J. Elsbree who will be the PCO moving forward. The Government has set up a new outlook Mailbox (764ESS.PK.AAS-V@us.af.mil ) and will be requesting that all industry correspondence include this mailbox. Update 11 July 2022: The Government anticipates the release of the Draft Request for Proposal for the U-A A&AS V requirement by end of this week. The Government is pleased to offer the opportunity for One-on-One discussions starting week 29 of this month. Appointments are available beginning at 14:00h Central European Time (CET) for 50-minute sessions every hour on Tuesday 19 July, Wednesday 20 July, and Thursday 21 July 2022. Additional appointments can be made available for the following week (week 30), also on Tuesday, Wednesday and Thursday, starting at 14:00h CET as well. Please, request an appointment in writing with a preferred date and time using 764ESS.PK.AAS-V@us.af.mil. | 45% | Special Notice | 03/11/2022 |
Additional Details
Solicitation Number
1305M326Q0505
Archive Date
Oct 6, 2026
Office Address
SEATTLE, WA, 98115